title: Mid-Term Administration of Tolvaptan Improves Renal Function Accompanied by Dose-Reduction in Furosemide in Aquaporin-Defined Responders.
authors.affiliation: Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, The University of Tokyo.
authors.forename: Teruhiko
authors.initials: T
authors.lastname: Imamura
authors.forename: Koichiro
authors.initials: K
authors.lastname: Kinugawa
mesh_terms: D065092:Antidiuretic Hormone Receptor Antagonists / Q000494:pharmacology; D020346:Aquaporins / Q000652:urine; D001127:Arginine Vasopressin / Q000097:blood; D001552:Benzazepines / Q000494:pharmacology*; D004232:Diuretics / Q000494:pharmacology; D005665:Furosemide / Q000494:pharmacology; D006333:Heart Failure / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007677:Kidney Function Tests; D054539:Medication Therapy Management; D018579:Patient Selection; D000077602:Tolvaptan
chemical_list: D065092:Antidiuretic Hormone Receptor Antagonists; D020346:Aquaporins; D001552:Benzazepines; D004232:Diuretics; D001127:Arginine Vasopressin; D000077602:Tolvaptan; D005665:Furosemide